This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25
tim.hodson Wed, 03/26/2025 - 14:25 March 17, 2025 Bayer recently announcedthat the U.S. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidneydisease (CKD). Accessed February 21, 2025. Accessed March 5, 2025. Accessed February 21, 2025.
18, 2025 About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, kidneydisease, type 2 diabetes and obesity.[1] DALLAS, Feb. 1] This cluster of chronic health conditions is called.
The first quarter of 2025 saw approvals in diabetes, depression, kidneydisease, and pain, among others. Read more about high-impact approvals of Q1 now.
Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidneydisease, or heart failure, as well as among adults with few cardiovascular risk factors.
This exciting overview highlights the top 10 AI-powered cardiometabolic startups poised to make significant impacts in 2025. Vitadio : Digital therapeutics for type 2 diabetes and prediabetes, expanding globally. LumineticsCore : An AI diagnostics company with FDA-cleared systems for detecting diabetic retinopathy.
On-demand access is available now and will remain open until December 2025. Diabetes Management: Gain insights into precision medicine, advanced insulin therapies, and continuous glucose monitoring (CGM) for cardiovascular risk assessment. When Will It Be Available?
tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across t he KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25
Stroke, Volume 56, Issue Suppl_1 , Page AWP289-AWP289, February 1, 2025. Background:The ABCD-GENE score, incorporating age, body mass index, chronic kidneydisease, diabetes, and CYP2C19 genotypes, is a validated risk score that integrates clinical risk factors with genetic information to predict clopidogrel response.
Stroke, Volume 56, Issue Suppl_1 , Page AWP319-AWP319, February 1, 2025. Reliability of self-reported risk factors was high in overweight (F1 0.81) and diabetes (F1 0.71), moderate in hearing impairment (F1 0.59) and hypertension (F1 0.56) and low in hypercholesterolemia (F1 0.49) and kidneydisease (F1 0.25).
Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025. Hypertension, diabetes, hyperlipidemia, and chronic kidneydisease are well-known cardiovascular risk factors for ICH. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.
Stroke, Volume 56, Issue Suppl_1 , Page AWP294-AWP294, February 1, 2025. Background:Racial disparities have been well described in cardiovascular disease. Patients were categorized into two groups, one with Black or African American and another with White race patients. Both groups were followed for 12 months.
Stroke, Volume 56, Issue Suppl_1 , Page ADP47-ADP47, February 1, 2025. Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.
Stroke, Volume 56, Issue Suppl_1 , Page ATP360-ATP360, February 1, 2025. Only age (point estimate 0.02, p=0.04) and history of chronic kidneydisease (point estimate 7.57, p<0.01) were significantly associated with elevated kynurenine concentrations in all stroke patients while controlling for covariables.
Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. female, 22.1%
Stroke, Volume 56, Issue Suppl_1 , Page AWP301-AWP301, February 1, 2025. VRFs included hypertension, diabetes, kidneydisease, smoking, drug or alcohol abuse, antithrombotic medication use, and sleep apnea. Introduction:While intracranial hemorrhage (ICH) is uncommon in young adults (18-55), its incidence is on the rise.
Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. In the U.S., SELECT Trial Results : Semaglutide 2.4
Written by Jesse McLaren An 80 year old patient with diabetes/hypertension/ cirrhosis had a recent increase in candesartan for their hypertension, and was also on spirolactone and nadolol. Acute hyperkalemia in the emergency department: a summary from a KidneyDisease: Improving Global Outcomes conference. References 1.
Mechanical complications such as free wall rupture, VSR and papillary muscle rupture is more likely to occur in patients who are older, female, hypertensive, have chronic kidneydisease, and have no prior history of smoking. link] [6] Contemporary Management of Post-MI Ventricular Septal Rupture - American College of Cardiology.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content